Overview
Design and analysis of clinical trials, statistical analysis of biomarker and high dimensional data, development and validation of prognostic and predictive models.
Current Appointments & Affiliations
James B. Duke Distinguished Professor of Biostatistics & Bioinformatics
·
2023 - Present
Biostatistics & Bioinformatics, Division of Biostatistics,
Biostatistics & Bioinformatics
Professor of Biostatistics & Bioinformatics
·
2012 - Present
Biostatistics & Bioinformatics, Division of Biostatistics,
Biostatistics & Bioinformatics
Chief, Division of Biostatistics
·
2019 - Present
Biostatistics & Bioinformatics,
Basic Science Departments
Member of the Duke Cancer Institute
·
1996 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Circulating Tumor DNA and Response to Cisplatin-based Chemotherapy in Patients with Metastatic Urothelial Carcinoma Enrolled in CALGB 90601 (Alliance).
Journal Article Eur Urol Open Sci · May 2025 BACKGROUND AND OBJECTIVE: Cisplatin-based chemotherapy has been a cornerstone of therapy for advanced/metastatic urothelial cancer (mUC). However, no genomic characteristics have been validated as prognostic biomarkers for this therapy. We sought to identi ... Full text Link to item CiteAfatinib in patients with solid tumors with neuregulin 1 (NRG1) fusions: a case series from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Journal Article ESMO Open · April 10, 2025 BACKGROUND: TAPUR is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and targetable genomic alterations. Results of four patients with various tumors with NRG1 fusions tre ... Full text Link to item CiteAssociations of COVID-19 vaccination with risks for post-infectious cardiovascular complications: an international cohort study in cancer patients with SARS-CoV-2 infection.
Journal Article Lancet Reg Health Am · April 2025 BACKGROUND: Whether COVID-19 vaccination is associated with risks for cardiovascular complications after SARS-CoV-2 infection in patients with cancer is unknown. The objective of this study was to investigate the associations between the two. METHODS: This ... Full text Link to item CiteRecent Grants
Research Triangle Center of Excellence in Regulatory Science and Innovation
ResearchPrincipal Investigator · Awarded by University of North Carolina - Chapel Hill · 2023 - 2028DoD: PCRP Clinical Consortium: Duke University Clinical Research Site
ResearchCo Investigator · Awarded by Department of Defense · 2007 - 2026Understanding heterogeneity and Improving the Precision of Prostate Cancer Clinical Outcomes in the Modern Era
ResearchPrincipal Investigator · Awarded by Department of Defense · 2023 - 2026View All Grants
Education, Training & Certifications
University of Texas Health Sciences Center, Houston ·
1994
Ph.D.